August 29, 2017 08:13 AM EDT

Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort

Shehla Shakoor

Managing Director

Seven years after Copenhagen-based Genmab inked a collaboration deal with Seattle Genetics, the US biotech has decided to opt-in on a development partnership. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort

Shehla Shakoor

Managing Director

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Sev­en years in the mak­ing, Seat­tle Ge­net­ics picks up ear­ly op­tion on Gen­mab's ADC ef­fort

Shehla Shakoor

Managing Director

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Seven years in the making, Seattle Genetics picks up early option on Genmab's ADC effort

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market